This prospective study examined normalized stability differences based on dominance side and visual feedback. Subjects with low back pain (LBP) (n=26; 9 men, 17 women) and without LBP (n=28; 11 men, 17 women) participated in this study. All subjects were asked to maintain single leg standing balance with the contralateral hip flexed 90° for 25s. The outcome measures included normalized holding duration and stability. The combined rotation (R(xyz)) was also calculated to compare the upper and lower thorax and lumbar axes relative to the core spine axis. The holding duration was significantly different between groups (T=-2.21, p=0.03). The subjects without recurrent LBP (control group) demonstrated longer hold duration times (24.60±4.2s) than the subjects with recurrent LBP (21.2±7.1s). For the normalized hold duration, there was a significant difference between groups based on visual input (F=7.13, p=0.009). There was also a significant difference in standing stability based on visual input (F=93.93, p=0.0001) and trunk area (F=101.51, p=0.0001). In addition, the normalized stability was significantly different based on dominance and visual input (F=11.28, p=0.002). Therefore, trunk stability could prompt an uncoordinated bracing effect with poor proprioception from injury to passive structures or due to interference of pain during central processing of information in subjects with recurrent LBP.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jelekin.2010.05.011 | DOI Listing |
Int J Stroke
January 2025
Medical University of South Carolina, Charleston, SC, USA.
Background: The usual antithrombotic treatment for symptomatic intracranial atherosclerotic stenosis (ICAS) consists of dual treatment with clopidogrel and aspirin for 90 days followed by aspirin alone but the risk of recurrent stroke remains high up to 12 months. The Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial was designed to determine whether other combinations of dual antithrombotic therapy are superior to clopidogrel and aspirin.
Methods: CAPTIVA is an ongoing, prospective, double-blinded, three-arm clinical trial at over 100 sites in the United States and Canada that will randomize 1683 high-risk subjects with a symptomatic infarct attributed to 70-99% stenosis of a major intracranial artery to 12 months of treatment with (1) ticagrelor (180 mg loading dose, then 90 mg twice daily), (2) low-dose rivaroxaban (2.
Biomolecules
December 2024
Laboratory of Vascular Pathology and Diabetes, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain.
Background: Plasma metabolites could be suitable as predictive biomarkers for cardiovascular pathologies or death, thereby improving the prediction of protein biomarkers. The release of acylcarnitines may be altered after coronary artery disease (CAD) in subjects with recurrent clinical outcomes, and this could be used as a prognosis tool.
Methods: Patients with stable coronary artery disease (SCAD) who had suffered an acute coronary syndrome 6-9 months before were followed for up to 4.
BMC Musculoskelet Disord
January 2025
Gold Coast University Hospital, 1 Hospital Boulevard, Gold Coast, Southport, QLD, 4215, Australia.
Background: Long term studies have shown the Latarjet procedure to be successful in preventing re-dislocation in primary and recurrent anterior inferior shoulder instability. It provides stability through the sling effect of the conjoint tendon and the bone block. It is unclear whether augmentation with capsular repair provides an added benefit or leads to restricted range of external rotation.
View Article and Find Full Text PDFBMC Infect Dis
January 2025
Department of Urology, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, Spain.
Background: Urinary tract infections (UTIs) are a significant global health issue, especially among women, with growing concerns related to antibiotic resistance and adverse effects. The Uromune, a sublingual, heat-inactivated, polybacterial vaccine, represents a promising therapeutic alternative by enhancing immune responses against uropathogens.
Methods: This pilot retrospective study, conducted at Hospital Universitari de Sant Joan de Reus from January 2018 to August 2022, assessed the association between Uromune administration and changes in recurrent UTIs.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!